Mardi, 28 Janvier 2020
Dernières nouvelles
Principale » Endo International PLC (ENDP) Issues FY17 Earnings Guidance

Endo International PLC (ENDP) Issues FY17 Earnings Guidance

30 Octobre 2017

Cantor Fitzgerald's price target would suggest a potential upside of 53.06% from the company's previous close. Four research analysts have rated the stock with a sell rating, fifteen have assigned a hold rating and five have given a buy rating to the company's stock. The mean target price as estimated by the analysts for the company has been recorded at $11.88.

In terms of Buy, Sell or Hold recommendations, Endo Int'l Plc (NASDAQ:ENDP) has analysts' mean recommendation of 2.8. Oppenheimer Holdings Inc. reaffirmed a "hold" rating on shares of Endo International PLC in a report on Tuesday, August 8th. Finally, Morgan Stanley cut their price target on Endo International PLC from $12.00 to $8.00 and set an equal weight rating on the stock in a research note on Thursday, August 10th.

Endo International plc (ENDP) stock is sinking -12.11% to $5.88.

Shares of Endo International PLC (ENDP) opened at 5.88 on Monday. The company had a trading volume of 11,689,342 shares. The company has a 50-day moving average of $8.31 and a 200-day moving average of $10.27.

Taking a broader look brokerage firms' analysts on the street with an expectant view have Endo Int'l Plc (NASDAQ:ENDP) high price target of $17 and with a conservative view have low price target of $7. It has a market cap of $1.49 Billion.

Sting musical The Last Ship to have United Kingdom premiere in Newcastle
The Last Ship is inspired by Sting's 1991 album The Soul Cages and his own childhood experiences. The new production is directed by Lorne Campbell and has set design by 59 Productions.

Endo International PLC (NASDAQ:ENDP) (TSE:ENL) issued an update on its third quarter earnings guidance on Monday morning. The company provided EPS guidance of $0.85 for the period, compared to the Thomson Reuters consensus EPS estimate of $0.67. The company issued revenue guidance of $3.38-3.53 billion, compared to the consensus revenue estimate of $3.47 billion.Endo International PLC also updated its Q3 guidance to $0.85 EPS.

Endo International plc (NASDAQ:ENDP) gross margin percentage stands at 37.6% while its operating margin for the past trailing twelve month is -99.9 percent and its overall profit margin (ttm) is 0 Percent. Endo International PLC's revenue for the quarter was down 4.9% on a year-over-year basis. During the same period a year ago, the business earned $0.86 EPS. On average, equities analysts anticipate that Endo International PLC will post $3.52 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This piece was first reported by StockNewsTimes and is the sole property of of StockNewsTimes.

Currently, Endo International plc (NASDAQ:ENDP) has an average volume of 6.24 Million. The shares were purchased at an average price of $7.89 per share, with a total value of $51,285.00. Following the transaction, the chief financial officer now directly owns 13,729 shares in the company, valued at $108,321.81. Also, COO Terrance J. Coughlin acquired 20,000 shares of the company's stock in a transaction on Thursday, August 10th. The stock exchanged hands 14.71 Million shares versus average trading capacity of 6.24 Million shares. Outstanding shares refer to a company's stock presently held by all its shareholders, counting share blocks held by institutional shareholders and restricted shares owned by the company's officers and insiders. The disclosure for this purchase can be found here. Teachers Advisors LLC raised its position in Endo International PLC by 1.9% in the 2nd quarter. This showed a surprise of 27.4% in the last quarter earnings. Canada Pension Plan Investment Board now owns 565,240 shares of the company's stock worth $6,314,000 after purchasing an additional 273,024 shares during the period. Corporate insiders own 0.50% of the company's stock.

Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services.